Bendetowicz, David
Fabbri, Margherita
Sirna, Federico
Fernagut, Pierre-Olivier
Foubert-Samier, Alexandra
Saulnier, Tiphaine
Le Traon, Anne Pavy
Proust-Lima, Cécile
Rascol, Olivier
Meissner, Wassilios G.
Article History
Accepted: 13 February 2024
First Online: 28 February 2024
Declarations
:
: M.F. received Grants from MSA Coalition, HORIZON 2022, Honoraria to speak from BIAL, AbbVie, Orkyn, Elivie, LvL médical and consultancies from Bial, Convatec and LvL médicale.A.F.S. received honoraria from Aguettant Laboratory and Sanofi, grants from the French Rare Disease Foundation, from the French regional health agency (Agence Régionale de Santé de nouvelle Aquitaine), and from France Parkinson association.W.G.M. reports personal fees from Elsevier, from Biohaven, Lundbeck, Roche, Servier, Alterity, Inhibikase, Teva and Takeda, outside the submitted work; and 1. International Parkinson and movement disorder society (Treasurer and Officer) 2. MSA Coalition (Member research steering committee) 3. Clément Fayat Foundation (Board of directors).A.P.L. reports honoraria from Biohaven, HAC Pharma and speaker fees from Alnylam, outside the submitted work.O.R. is advising following compagnies AbbVie, Acorda, Aguettant, Alkahest, AlzProtect, Apopharma, Astrazeneca, Bial, Biogen, Britannia, Buckwang, Cerevel, Clevexel, Contera, GE Healthcare, Handltherapeutic, Ionis, Irlab, Jazz, Kyowa, LGD Nuvamid, Lundbeck, Merck, Merz, MundiPharma, Neuralight, Neuratris, Neuroderm, Novartis, ONO Pharma, Orion Pharma, Parexel, PD Neurotechnology, Pfizer, Polycaps, Prexton, Roche Therapeutics, Sanofi, Scienture, Servier, Sombiotech, Sunovion, Supernus, Synagile, Thelonius Mind, Takeda, Théranexus, Teva, Tools4patient, UCB, Vision 2 voice, Zambon.C.P.L., D.B., F.S., P.O.F., and T.S. have nothing to disclose.
: This article does not contain any studies with human or animal subjects performed by any of the authors.